The percentage of patients with a CV port was significantly higher in the EGFR-inhibitor group than in the VEGF-inhibitor group (P < 0.001); however, the other parameters, including the risk factor scores for thromboembolism in cancer patients, did not significantly differ between the groups (Table 1). The gene discussed is VEGFA; the disease is cancer.